Retrophin (NASDAQ:RTRX) Upgraded at Zacks Investment Research
According to Zacks, “Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company’s approved products include Chenodal®, Cholbam, and Thiola®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis, pantothenate kinase-associated neurodegeneration, infantile spasms, nephrotic syndrome and others. Retrophin, Inc. is based in San Diego. “
RTRX has been the topic of several other reports. William Blair restated a buy rating on shares of Retrophin in a report on Friday, July 5th. ValuEngine lowered shares of Zumiez from a hold rating to a sell rating in a report on Tuesday, July 2nd. Barclays assumed coverage on shares of GENFIT S A/ADR in a report on Monday, April 22nd. They issued an overweight rating and a $55.00 price objective on the stock. BidaskClub upgraded shares of Xilinx from a hold rating to a buy rating in a report on Saturday, June 29th. Finally, Canaccord Genuity restated a speculative buy rating and issued a GBX 70 ($0.91) price objective on shares of Bacanora Lithium in a report on Monday, July 1st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company’s stock. Retrophin currently has a consensus rating of Buy and a consensus target price of $44.50.
Retrophin (NASDAQ:RTRX) last announced its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.41). The business had revenue of $39.57 million for the quarter, compared to analysts’ expectations of $41.40 million. Retrophin had a negative net margin of 75.75% and a negative return on equity of 41.38%. The firm’s revenue was up 3.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.14) EPS. As a group, equities analysts forecast that Retrophin will post -3.02 earnings per share for the current year.
In other Retrophin news, insider William E. Rote sold 1,625 shares of the stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $17.77, for a total value of $28,876.25. The sale was disclosed in a filing with the SEC, which is available through this link. Also, COO Neil F. Mcfarlane sold 1,968 shares of the stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $18.25, for a total transaction of $35,916.00. Following the completion of the sale, the chief operating officer now directly owns 27,972 shares in the company, valued at $510,489. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 10,819 shares of company stock worth $194,503. 4.32% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Perceptive Advisors LLC grew its position in shares of Retrophin by 4.0% in the 4th quarter. Perceptive Advisors LLC now owns 3,342,038 shares of the biopharmaceutical company’s stock valued at $49,782,000 after buying an additional 129,167 shares during the last quarter. Macquarie Group Ltd. grew its position in shares of Retrophin by 17.6% in the 4th quarter. Macquarie Group Ltd. now owns 2,265,924 shares of the biopharmaceutical company’s stock valued at $51,278,000 after buying an additional 339,588 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Retrophin by 3.9% in the 1st quarter. The Manufacturers Life Insurance Company now owns 1,944,288 shares of the biopharmaceutical company’s stock valued at $43,999,000 after buying an additional 73,284 shares during the last quarter. Bank of America Corp DE grew its position in shares of Retrophin by 114.4% in the 4th quarter. Bank of America Corp DE now owns 1,223,705 shares of the biopharmaceutical company’s stock valued at $27,693,000 after buying an additional 652,895 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of Retrophin by 6.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,154,859 shares of the biopharmaceutical company’s stock valued at $26,134,000 after buying an additional 67,834 shares during the last quarter.
Retrophin Company Profile
Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.
Read More: Balanced Fund
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.